Transarterial embolization therapies for the treatment of hepatocellular carcinoma: CEPO review and clinical recommendations

HPB

Volumn 17, Issue 1, 2015, Pages 52-65

  Boily, Gino ^a   Villeneuve, Jean Pierre ^b   Lacoursière, Luc ^c   Chaudhury, Prosanto ^d   Couture, Félix ^e   Ouellet, Jean François ^e   Lapointe, Réal ^b   Goulet, Stéphanie ^a   Gervais, Normand ^f   Almanric, Karine ^g   Bouchard, Philippe ^h   Boulanger, Jim ^a   Cournoyer, Ghislain ⁱ   Guay, Marie Pascale ^j   Jamal, Rahima ^k   Lespérance, Bernard ^l   Letarte, Nathalie ^k   Pineau, Gilles ^a   Rajan, Raghu ^m   Roy, Isabelle ^g   Samson, Benoît ⁿ   Vincent, François ^o   more..

^a 2535 boulevard Laurier   (Canada)

^b UNIVERSITY OF MONTREAL   (Canada)

^c Hotel Dieu de Levis Hospital   (Canada)

^d ROYAL VICTORIA HOSPITAL   (Canada)

^e LAVAL UNIVERSITY   (Canada)

^f Centre Hospitalier Régional du Grand Portage CSSS de Rivière du Loup   (Canada)

^g Hôpital Cité de la Santé et Direction de Santé Publique de Laval   (Canada)

^h MAISONNEUVE ROSEMONT HOSPITAL   (Canada)

ⁱ Hôpital Régional de Saint Jérôme CSSS de Saint Jérôme   (Canada)

^j MCGILL UNIVERSITY   (Canada)

^k NOTRE DAME HOSPITAL   (Canada)

^l HÔPITAL DU SACRÉ COEUR DE MONTRÉAL   (Canada)

^m MONTREAL GENERAL HOSPITAL   (Canada)

ⁿ HÔPITAL CHARLES LEMOYNE   (Canada)

^o Centre Hospitalier Regional   (Canada)

more..

Author keywords

[No Author keywords available]

Indexed keywords

NANOBEAD; SORAFENIB; TRIACYLGLYCEROL LIPASE;

ALOPECIA; ARTICLE; ARTIFICIAL EMBOLISM; ASCITES; BRAIN DISEASE; CANCER MORTALITY; CANCER PALLIATIVE THERAPY; CANCER SURVIVAL; CHOLECYSTITIS; CLINICAL PRACTICE; COMPARATIVE EFFECTIVENESS; DESQUAMATION; DIARRHEA; DRUG ELUTING BEAD TRANSARTERIAL CHEMOEMBOLIZATION; DRUG ERUPTION; EMBOLIC PARTICLE; EVIDENCE BASED PRACTICE; GASTROINTESTINAL HEMORRHAGE; HAND FOOT SYNDROME; HEMATOLOGIC DISEASE; HUMAN; HYPERTENSION; LIVER CELL CARCINOMA; LIVER FAILURE; META ANALYSIS; MULTIMODALITY CANCER THERAPY; OVERALL SURVIVAL; PATIENT SAFETY; PATIENT SELECTION; PRACTICE GUIDELINE; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK ASSESSMENT; SIDE EFFECT; SKIN MANIFESTATION; SYSTEMATIC REVIEW; TRANSARTERIAL CHEMOEMBOLIZATION THERAPY; TRANSARTERIAL RADIOEMBOLIZATION THERAPY; TRIACYLGLYCEROL LIPASE BLOOD LEVEL; ADVERSE EFFECTS; CANCER STAGING; CARCINOMA, HEPATOCELLULAR; CHEMOEMBOLIZATION; LIVER NEOPLASMS; MORTALITY; PALLIATIVE THERAPY; PATHOLOGY; RISK FACTOR; STANDARDS; SURVIVAL ANALYSIS; SURVIVAL RATE; TIME FACTOR; TREATMENT OUTCOME;

CARCINOMA, HEPATOCELLULAR; CHEMOEMBOLIZATION, THERAPEUTIC; HUMANS; LIVER NEOPLASMS; NEOPLASM STAGING; PALLIATIVE CARE; PATIENT SELECTION; RISK FACTORS; SURVIVAL ANALYSIS; SURVIVAL RATE; TIME FACTORS; TREATMENT OUTCOME;

EID: 84916200950     PISSN: 1365182X     EISSN: 14772574     Source Type: Journal    
DOI: 10.1111/hpb.12273     Document Type: Article

References (71)

1. McGlynn KA, London WT,. (2005) Epidemiology and natural history of hepatocellular carcinoma. Best Pract Res Clin Gastroenterol 19: 3-23.
2. Comité consultatif de la Société canadienne du cancer. (2013) Statistiques canadiennes sur le cancer, 2013. Toronto, ON: Société canadienne du cancer.
3. Bruix J, Sherman M,. (2011) Management of hepatocellular carcinoma: an update. Hepatology 53: 1020-1022.
4. Lencioni R, Crocetti L,. (2012) Local-regional treatment of hepatocellular carcinoma. Radiology 262: 43-58.
5. Cook DJ, Guyatt GH, Laupacis A, Sackett DL,. (1992) Rules of evidence and clinical recommendations on the use of antithrombotic agents. Chest 102 (4 Suppl.): 305S-311S.
6. Groupe d'Etude et de Traitement du Carcinome Hépatocellulaire. (1995) A comparison of lipiodol chemoembolization and conservative treatment for unresectable hepatocellular carcinoma. N Engl J Med 332: 1256-1261.
7. Doffoel M, Bonnetain F, Bouche O, Vetter D, Abergel A, Fratte S, et al. (2008) Multicentre randomised phase III trial comparing tamoxifen alone or with transarterial lipiodol chemoembolisation for unresectable hepatocellular carcinoma in cirrhotic patients (Fédération Francophone de Cancérologie Digestive 9402). Eur J Cancer 44: 528-538.
8. Llovet JM, Real MI, Montana X, Planas R, Coll S, Aponte J, et al. (2002) Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet 359: 1734-1739.
9. Lo CM, Ngan H, Tso WK, Liu CL, Lam CM, Poon RT, et al. (2002) Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 35: 1164-1171.
10. Pelletier G, Ducreux M, Gay F, Luboinski M, Hagege H, Dao T, et al. (1998) Treatment of unresectable hepatocellular carcinoma with lipiodol chemoembolization: a multicenter randomized trial. Groupe CHC. J Hepatol 29: 129-134.
11. Pelletier G, Roche A, Ink O, Anciaux ML, Derhy S, Rougier P, et al. (1990) A randomized trial of hepatic arterial chemoembolization in patients with unresectable hepatocellular carcinoma. J Hepatol 11: 181-184.
12. Yuen MF, Chan AO, Wong BC, Hui CK, Ooi GC, Tso WK, et al. (2003) Transarterial chemoembolization for inoperable, early stage hepatocellular carcinoma in patients with Child-Pugh grade A and B: results of a comparative study in 96 Chinese patients. Am J Gastroenterol 98: 1181-1185.
13. Bronowicki JP, Boudjema K, Chone L, Nisand G, Bazin C, Pflumio F, et al. (1996) Comparison of resection, liver transplantation and transcatheter oily chemoembolization in the treatment of hepatocellular carcinoma. J Hepatol 24: 293-300.
14. Bronowicki JP, Vetter D, Dumas F, Boudjema K, Bader R, Weiss AM, et al. (1994) Transcatheter oily chemoembolization for hepatocellular carcinoma. A 4-year study of 127 French patients. Cancer 74: 16-24.
15. Huang YH, Wu JC, Chen SC, Chen CH, Chiang JH, Huo TI, et al. (2006) Survival benefit of transcatheter arterial chemoembolization in patients with hepatocellular carcinoma larger than 10 cm in diameter. Aliment Pharmacol Ther 23: 129-135.
16. Stefanini GF, Amorati P, Biselli M, Mucci F, Celi A, Arienti V, et al. (1995) Efficacy of transarterial targeted treatments on survival of patients with hepatocellular carcinoma. An Italian experience. Cancer 75: 2427-2434.
17. Vetter D, Wenger JJ, Bergier JM, Doffoel M, Bockel R,. (1991) Transcatheter oily chemoembolization in the management of advanced hepatocellular carcinoma in cirrhosis: results of a Western comparative study in 60 patients. Hepatology 13: 427-433.
18. Llovet JM, Bruix J,. (2003) Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology 37: 429-442.
19. Marelli L, Stigliano R, Triantos C, Senzolo M, Cholongitas E, Davies N, et al. (2007) Transarterial therapy for hepatocellular carcinoma: which technique is more effective? A systematic review of cohort and randomized studies. Cardiovasc Intervent Radiol 30: 6-25.
20. Oliveri RS, Wetterslev J, Gluud C,. (2011) Transarterial (chemo)embolisation for unresectable hepatocellular carcinoma. Cochrane Database Syst Rev (3) CD004787.
21. Toro A, Pulvirenti E, Palermo F, Di Carlo I,. (2012) Health-related quality of life in patients with hepatocellular carcinoma after hepatic resection, transcatheter arterial chemoembolization, radiofrequency ablation or no treatment. Surg Oncol 21: e23-e30.
22. Bruix J, Llovet JM, Castells A, Montana X, Bru C, Ayuso MC, et al. (1998) Transarterial embolization versus symptomatic treatment in patients with advanced hepatocellular carcinoma: results of a randomized, controlled trial in a single institution. Hepatology 27: 1578-1583.
23. Chang JM, Tzeng WS, Pan HB, Yang CF, Lai KH,. (1994) Transcatheter arterial embolization with or without cisplatin treatment of hepatocellular carcinoma. A randomized controlled study. Cancer 74: 2449-2453.
24. Kawai S, Okamura J, Ogawa M, Ohashi Y, Tani M, Inoue J, et al. (1992) Prospective and randomized clinical trial for the treatment of hepatocellular carcinoma-a comparison of lipiodol-transcatheter arterial embolization with and without adriamycin (first cooperative study). The Cooperative Study Group for Liver Cancer Treatment of Japan. Cancer Chemother Pharmacol 31 (Suppl.): S1-S6.
25. Morse MA, Hanks BA, Suhocki P, Doan PL, Liu EA, Frost P, et al. (2012) Improved time to progression for transarterial chemoembolization compared with transarterial embolization for patients with unresectable hepatocellular carcinoma. Clin Colorectal Cancer 11: 185-190.
26. Malagari K, Pomoni M, Kelekis A, Pomoni A, Dourakis S, Spyridopoulos T, et al. (2010) Prospective randomized comparison of chemoembolization with doxorubicin-eluting beads and bland embolization with BeadBlock for hepatocellular carcinoma. Cardiovasc Intervent Radiol 33: 541-551.
27. Brown KT, Gonen M, Do KG, Covey AM, Getrajdman GI, Zhao B, et al. (2013) A randomized single blind controlled trial of beads versus doxorubicin-eluting beads for arterial embolization of hepatocellular carcinoma (HCC). J Clin Oncol 31 (4-Suppl.): 143.
28. Lammer J, Malagari K, Vogl T, Pilleul F, Denys A, Watkinson A, et al. (2010) Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study. Cardiovasc Intervent Radiol 33: 41-52.
29. Sacco R, Bargellini I, Bertini M, Bozzi E, Romano A, Petruzzi P, et al. (2011) Conventional versus doxorubicin-eluting bead transarterial chemoembolization for hepatocellular carcinoma. J Vasc Interv Radiol 22: 1545-1552.
30. van Malenstein H, Maleux G, Vandecaveye V, Heye S, Laleman W, van Pelt J, et al. (2011) A randomized phase II study of drug-eluting beads versus transarterial chemoembolization for unresectable hepatocellular carcinoma. Onkologie 34: 368-376.
31. Dhanasekaran R, Kooby DA, Staley CA, Kauh JS, Khanna V, Kim HS,. (2010) Comparison of conventional transarterial chemoembolization (TACE) and chemoembolization with doxorubicin drug eluting beads (DEB) for unresectable hepatocelluar carcinoma (HCC). J Surg Oncol 101: 476-480.
32. Song MJ, Chun HJ, Song do S, Kim HY, Yoo SH, Park CH, et al. (2012) Comparative study between doxorubicin-eluting beads and conventional transarterial chemoembolization for treatment of hepatocellular carcinoma. J Hepatol 57: 1244-1250.
33. Song MJ, Park CH, Kim JD, Kim HY, Bae SH, Choi JY, et al. (2011) Drug-eluting bead loaded with doxorubicin versus conventional Lipiodol-based transarterial chemoembolization in the treatment of hepatocellular carcinoma: a case-control study of Asian patients. Eur J Gastroenterol Hepatol 23: 521-527.
34. Wiggermann P, Sieron D, Brosche C, Brauer T, Scheer F, Platzek I, et al. (2011) Transarterial chemoembolization of Child-A hepatocellular carcinoma: drug-eluting bead TACE (DEB TACE) vs. TACE with cisplatin/lipiodol (cTACE). Med Sci Monit 17: CR189-CR195.
35. Gao S, Yang Z, Zheng Z, Yao J, Deng M, Xie H, et al. (2013) Doxorubicin-eluting bead versus conventional TACE for unresectable hepatocellular carcinoma: a meta-analysis. Hepatogastroenterology 60: 813-820.
36. Vogl TJ, Lammer J, Lencioni R, Malagari K, Watkinson A, Pilleul F, et al. (2011) Liver, gastrointestinal, and cardiac toxicity in intermediate hepatocellular carcinoma treated with PRECISION TACE with drug-eluting beads: results from the PRECISION V randomized trial. AJR Am J Roentgenol 197: W562-W570.
37. Carr BI, Kondragunta V, Buch SC, Branch RA,. (2010) Therapeutic equivalence in survival for hepatic arterial chemoembolization and yttrium 90 microsphere treatments in unresectable hepatocellular carcinoma: a two-cohort study. Cancer 116: 1305-1314.
38. Kooby DA, Egnatashvili V, Srinivasan S, Chamsuddin A, Delman KA, Kauh J, et al. (2010) Comparison of yttrium-90 radioembolization and transcatheter arterial chemoembolization for the treatment of unresectable hepatocellular carcinoma. J Vasc Interv Radiol 21: 224-230.
39. Moreno-Luna LE, Yang JD, Sanchez W, Paz-Fumagalli R, Harnois DM, Mettler TA, et al. (2013) Efficacy and safety of transarterial radioembolization versus chemoembolization in patients with hepatocellular carcinoma. Cardiovasc Intervent Radiol 36: 714-723.
40. Salem R, Lewandowski RJ, Kulik L, Wang E, Riaz A, Ryu RK, et al. (2011) Radioembolization results in longer time-to-progression and reduced toxicity compared with chemoembolization in patients with hepatocellular carcinoma. Gastroenterology 140: 497-507.
41. Xie F, Zang J, Guo X, Xu F, Shen R, Yan L, et al. (2012) Comparison of transcatheter arterial chemoembolization and microsphere embolization for treatment of unresectable hepatocellular carcinoma: a meta-analysis. J Cancer Res Clin Oncol 138: 455-462.
42. Kudo M, Imanaka K, Chida N, Nakachi K, Tak WY, Takayama T, et al. (2011) Phase III study of sorafenib after transarterial chemoembolisation in Japanese and Korean patients with unresectable hepatocellular carcinoma. Eur J Cancer 47: 2117-2127.
43. Sansonno D, Lauletta G, Russi S, Conteduca V, Sansonno L, Dammacco F,. (2012) Transarterial chemoembolization plus sorafenib: a sequential therapeutic scheme for HCV-related intermediate-stage hepatocellular carcinoma: a randomized clinical trial. Oncologist 17: 359-366.
44. Lencioni R, Llovet JM, Han G, Tak WY, Yang J, Leberre M-A, et al. (2012) Sorafenib or placebo in combination with transarterial chemoembolization (TACE) with doxorubicin-eluting beads (DEBDOX) for intermediate-stage hepatocellular carcinoma (HCC): phase II, randomized, double-blind SPACE trial. J Clin Oncol 30 (4-Suppl.): LBA154.
45. Qu XD, Chen CS, Wang JH, Yan ZP, Chen JM, Gong GQ, et al. (2012) The efficacy of TACE combined sorafenib in advanced stages hepatocellullar carcinoma. BMC Cancer 12: 263.
46. Tan WF, Qiu ZQ, Yu Y, Ran RZ, Yi B, Lau WY, et al. (2010) Sorafenib extends the survival time of patients with multiple recurrences of hepatocellular carcinoma after liver transplantation. Acta Pharmacol Sin 31: 1643-1648.
47. Forner A, Llovet JM, Bruix J,. (2012) Chemoembolization for intermediate HCC: is there proof of survival benefit? J Hepatol 56: 984-986.
48. Ray CE Jr, Haskal ZJ, Geschwind JF, Funaki BS,. (2011) The use of transarterial chemoembolization in the treatment of unresectable hepatocellular carcinoma: a response to the Cochrane Collaboration review of 2011. J Vasc Interv Radiol 22: 1693-1696.
49. Rose SC, Kikolski SG, Gish RG, Kono Y, Loomba R, Hemming AW, et al. (2013) Society of interventional radiology critique and commentary on the cochrane report on transarterial chemoembolization. Hepatology 57: 1675-1676.
50. Akamatsu M, Yoshida H, Obi S, Sato S, Koike Y, Fujishima T, et al. (2004) Evaluation of transcatheter arterial embolization prior to percutaneous tumor ablation in patients with hepatocellular carcinoma: a randomized controlled trial. Liver Int 24: 625-629.
51. Brown DB, Nikolic B, Covey AM, Nutting CW, Saad WE, Salem R, et al. (2012) Quality improvement guidelines for transhepatic arterial chemoembolization, embolization, and chemotherapeutic infusion for hepatic malignancy. J Vasc Interv Radiol 23: 287-294.
52. Raoul JL, Sangro B, Forner A, Mazzaferro V, Piscaglia F, Bolondi L, et al. (2011) Evolving strategies for the management of intermediate-stage hepatocellular carcinoma: available evidence and expert opinion on the use of transarterial chemoembolization. Cancer Treat Rev 37: 212-220.
53. Salem R, Gilbertsen M, Butt Z, Memon K, Vouche M, Hickey R, et al. (2013) Increased quality of life among hepatocellular carcinoma patients treated with radioembolization, compared with chemoembolization. Clin Gastroenterol Hepatol 11: 1358-1365.
54. Sato K, Lewandowski RJ, Bui JT, Omary R, Hunter RD, Kulik L, et al. (2006) Treatment of unresectable primary and metastatic liver cancer with yttrium-90 microspheres (TheraSphere): assessment of hepatic arterial embolization. Cardiovasc Intervent Radiol 29: 522-529.
55. Xue TC, Xie XY, Zhang L, Yin X, Zhang BH, Ren ZG,. (2013) Transarterial chemoembolization for hepatocellular carcinoma with portal vein tumor thrombus: a meta-analysis. BMC Gastroenterol 13: 60.
56. Chung GE, Lee JH, Kim HY, Hwang SY, Kim JS, Chung JW, et al. (2011) Transarterial chemoembolization can be safely performed in patients with hepatocellular carcinoma invading the main portal vein and may improve the overall survival. Radiology 258: 627-634.
57. Kim KM, Kim JH, Park IS, Ko GY, Yoon HK, Sung KB, et al. (2009) Reappraisal of repeated transarterial chemoembolization in the treatment of hepatocellular carcinoma with portal vein invasion. J Gastroenterol Hepatol 24: 806-814.
58. Lee HS, Kim JS, Choi IJ, Chung JW, Park JH, Kim CY,. (1997) The safety and efficacy of transcatheter arterial chemoembolization in the treatment of patients with hepatocellular carcinoma and main portal vein obstruction. A prospective controlled study. Cancer 79: 2087-2094.
59. Luo J, Guo RP, Lai EC, Zhang YJ, Lau WY, Chen MS, et al. (2011) Transarterial chemoembolization for unresectable hepatocellular carcinoma with portal vein tumor thrombosis: a prospective comparative study. Ann Surg Oncol 18: 413-420.
60. Niu ZJ, Ma YL, Kang P, Ou SQ, Meng ZB, Li ZK, et al. (2012) Transarterial chemoembolization compared with conservative treatment for advanced hepatocellular carcinoma with portal vein tumor thrombus: using a new classification. Med Oncol 29: 2992-2997.
61. Peng ZW, Guo RP, Zhang YJ, Lin XJ, Chen MS, Lau WY,. (2012) Hepatic resection versus transcatheter arterial chemoembolization for the treatment of hepatocellular carcinoma with portal vein tumor thrombus. Cancer 118: 4725-4736.
62. Yodono H, Matsuo K, Shinohara A,. (2011) A retrospective comparative study of epirubicin-lipiodol emulsion and cisplatin-lipiodol suspension for use with transcatheter arterial chemoembolization for treatment of hepatocellular carcinoma. Anticancer Drugs 22: 277-282.
63. Zhou Q, Wang Y, Zhou X, Peng B, Yang J, Liang L, et al. (2011) Prognostic analysis for treatment modalities in hepatocellular carcinomas with portal vein tumor thrombi. Asian Pac J Cancer Prev 12: 2847-2850.
64. Llovet JM, Bru C, Bruix J,. (1999) Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis 19: 329-338.
65. Ramsey DE, Geschwind JF,. (2002) Chemoembolization of hepatocellular carcinoma-what to tell the skeptics: review and meta-analysis. Tech Vasc Interv Radiol 5: 122-126.
66. Lencioni R, de Baere T, Burrel M, Caridi JG, Lammer J, Malagari K, et al. (2012) Transcatheter treatment of hepatocellular carcinoma with doxorubicin-loaded DC bead (DEBDOX): technical recommendations. Cardiovasc Intervent Radiol 35: 980-985.
67. Sieghart W, Hucke F, Pinter M, Graziadei I, Vogel W, Muller C, et al. (2013) The ART of decision making: retreatment with transarterial chemoembolization in patients with hepatocellular carcinoma. Hepatology 57: 2261-2273.
68. Edeline J, Boucher E, Rolland Y, Vauleon E, Pracht M, Perrin C, et al. (2012) Comparison of tumor response by Response Evaluation Criteria in Solid Tumors (RECIST) and modified RECIST in patients treated with sorafenib for hepatocellular carcinoma. Cancer 118: 147-156.
69. Gillmore R, Stuart S, Kirkwood A, Hameeduddin A, Woodward N, Burroughs AK, et al. (2011) EASL and mRECIST responses are independent prognostic factors for survival in hepatocellular cancer patients treated with transarterial embolization. J Hepatol 55: 1309-1316.
70. Bruix J, Sherman M, Llovet JM, Beaugrand M, Lencioni R, Burroughs AK, et al. (2001) Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol 35: 421-430.
71. Lencioni R, Llovet JM,. (2010) Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis 30: 52-60.